Research Analysts Issue Forecasts for AKRO FY2029 Earnings

Akero Therapeutics, Inc. (NASDAQ:AKRO) – Stock analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Akero Therapeutics in a research note issued on Monday, January 27th. HC Wainwright analyst E. Arce forecasts that the company will post earnings per share of $5.58 for the year. HC Wainwright has a “Buy” rating and a $72.00 price target on the stock. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.96) per share.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15).

A number of other brokerages also recently issued reports on AKRO. Canaccord Genuity Group raised their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday. Citigroup boosted their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Morgan Stanley lifted their price objective on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research report on Tuesday. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.57.

Akero Therapeutics Stock Up 4.9 %

Shares of NASDAQ AKRO opened at $54.00 on Wednesday. The company has a 50 day simple moving average of $29.31 and a 200-day simple moving average of $28.51. The company has a market capitalization of $3.77 billion, a P/E ratio of -14.40 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics has a 1 year low of $15.32 and a 1 year high of $58.40.

Insider Activity at Akero Therapeutics

In other news, VP Patrick Lamy sold 925 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total transaction of $28,480.75. Following the transaction, the vice president now directly owns 17,858 shares in the company, valued at $549,847.82. The trade was a 4.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Cheng sold 108,366 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $31.73, for a total transaction of $3,438,453.18. Following the transaction, the chief executive officer now owns 605,417 shares in the company, valued at $19,209,881.41. The trade was a 15.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 323,870 shares of company stock valued at $11,751,090 over the last ninety days. Insiders own 7.94% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its position in Akero Therapeutics by 54.4% during the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after buying an additional 2,782,029 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Akero Therapeutics by 2.9% during the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock valued at $203,053,000 after buying an additional 201,225 shares during the period. RTW Investments LP lifted its stake in shares of Akero Therapeutics by 9.0% during the third quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock valued at $169,829,000 after buying an additional 487,450 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Akero Therapeutics during the third quarter valued at approximately $37,392,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Akero Therapeutics by 4,022.1% in the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock valued at $16,636,000 after purchasing an additional 583,486 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.